No Data
No Data
William Blair Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
William Blair Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.5%, Underperforms Competitors
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
Analysts Offer Insights on Healthcare Companies: Cybin (CYBN) and Corbus Pharmaceuticals (CRBP)
J L 7 2 : Now even good news is of no use, the stock price is plummeting
.